Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country save search
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Published: 2023-12-21 (Crawled : 14:00) - biospace.com/
SONN | $1.82 -9.0% -9.89% 46K
|
Health Technology
|
| O: 2.58%
H: 16.87%
C: 16.25%
son-1210 first publication tumor immunotherapy
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
RLYB | $1.83 -16.82% -20.22% 1.7M
|
|
| O: 1.03%
H: 11.22%
C: -6.46%
rlyb116
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
Published: 2023-12-19 (Crawled : 17:00) - biospace.com/
DGX | $128.64 0.09% 0.0% 700K
|
Health Services
|
| O: 0.17%
H: 0.59%
C: 0.29%
test diagnostics
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
Published: 2023-12-19 (Crawled : 14:00) - biospace.com/
NRXP | $4.9 -4.3% -4.49% 210K
|
Manufacturing
|
| O: -4.99%
H: 10.0%
C: -2.48%
ketamine depression treatment pharmaceuticals agreement
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 19, 2023
Published: 2023-12-19 (Crawled : 14:00) - biospace.com/
SDGR | $25.56 -3.37% -3.48% 710K
|
Technology Services
|
| O: 1.85%
H: 3.75%
C: 2.31%
nasdaq grants
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
europe commercialization migraine agreement
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
MRK | $126.19 0.36% 0.15% 6.2M
|
Health Technology
|
| O: 1.0%
H: 0.99%
C: -0.11%
keytruda tumors advanced plus
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Published: 2023-12-12 (Crawled : 20:00) - biospace.com/
PTPI | $0.8041 -3.57% -3.71% 540K
|
|
| O: 16.38%
H: 31.76%
C: -7.78%
first pharmaceuticals study
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
RCKT S | $24.01 -0.74% -0.75% 580K
|
Health Technology
|
| O: 0.12%
H: 2.9%
C: 2.42%
pharmaceuticals
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.36%
H: 0.14%
C: -0.22%
initiative health awards grants
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
LUCD | $0.8046 -0.54% -0.55% 360K
|
|
| O: 2.19%
H: 2.71%
C: -2.86%
PAVM | $1.925 -0.26% -0.26% 49K
|
Health Technology
|
| O: 0.0%
H: 32.9%
C: 24.84%
positive publication diagnostics results
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
LEGN | $51.71 -2.29% -2.34% 970K
|
Health Technology
|
| O: 0.78%
H: 3.23%
C: 2.76%
carvykti life treatment study
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
treatment lymphomas potential
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
unique treatment
Terumo Medical Corporation's New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
TRUMF | $17.312 -17.59% 2.2K
|
Health Technology
|
| O: 1.44%
H: 1.37%
C: 0.0%
TRUMY | $16.76 0.79% 32K
|
Manufacturing
|
| O: 3.39%
H: 0.0%
C: -3.23%
solution system medical
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-12-11 (Crawled : 14:00) - biospace.com/
ATNM | $8.44 -6.22% 0.0% 250K
|
Health Technology
|
| O: 6.77%
H: 0.35%
C: -13.38%
positive leukemia
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.42%
H: 1.23%
C: 1.13%
breyanzi treatment leukemia
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-07 (Crawled : 00:00) - biospace.com/
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
conference
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
Published: 2023-12-07 (Crawled : 00:00) - biospace.com/
ANGO | $6.32 -0.78% -0.79% 600K
|
Health Technology
|
| O: 0.89%
H: 3.51%
C: 2.93%
treatment system study
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
APDN | $0.3622 -4.38% -4.58% 120K
|
Commercial Services
|
| O: 2.02%
H: 7.92%
C: 2.17%
report year dna financial results
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.